Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
D'Amico R, Yang Y, Mildvan D, Evans SR, Schnizlein-Bick CT, Hafner R, Webb N, Basar M, Zackin R, Jacobson MA. D'Amico R, et al. Among authors: zackin r. J Clin Immunol. 2005 Mar;25(2):106-15. doi: 10.1007/s10875-005-2816-0. J Clin Immunol. 2005. PMID: 15821887 Clinical Trial.
Changes in weight and lean body mass during highly active antiretroviral therapy.
Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, Evans S, Mulligan K; AIDS Clinical Trial Group 892 Team. Shikuma CM, et al. Among authors: zackin r. Clin Infect Dis. 2004 Oct 15;39(8):1223-30. doi: 10.1086/424665. Epub 2004 Sep 27. Clin Infect Dis. 2004. PMID: 15486848 Clinical Trial.
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy.
Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, Wheat LJ, Nyangweso PM, Yiannoutsos CT, Schnizlein-Bick CT, Owens S, Aberg JA; AIDS Clinical Trials Group A5038 Study Group. Goldman M, et al. Among authors: zackin r. Clin Infect Dis. 2004 May 15;38(10):1485-9. doi: 10.1086/420749. Epub 2004 Apr 28. Clin Infect Dis. 2004. PMID: 15156489
Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity.
Wohl DA, Pilcher CD, Evans S, Revuelta M, McComsey G, Yang Y, Zackin R, Alston B, Welch S, Basar M, Kashuba A, Kondo P, Martinez A, Giardini J, Quinn J, Littles M, Wingfield H, Koletar SL; Adult AIDS Clinical Trials Group A5129 Team. Wohl DA, et al. Among authors: zackin r. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):274-8. doi: 10.1097/00126334-200403010-00008. J Acquir Immune Defic Syndr. 2004. PMID: 15076242 Clinical Trial.
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ; ACTG 5087 Study Team. Aberg JA, et al. Among authors: zackin ra. AIDS Res Hum Retroviruses. 2005 Sep;21(9):757-67. doi: 10.1089/aid.2005.21.757. AIDS Res Hum Retroviruses. 2005. PMID: 16218799 Clinical Trial.
Predictive value of HIV-1 viral load on risk for opportunistic infection.
Swindells S, Evans S, Zackin R, Goldman M, Haubrich R, Filler SG, Balfour HH Jr; AIDS Clinical Trial Group 722 Study Team. Swindells S, et al. Among authors: zackin r. J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):154-8. doi: 10.1097/00042560-200206010-00003. J Acquir Immune Defic Syndr. 2002. PMID: 12045677 Clinical Trial.
31 results